Breaking News

WellSpring Appoints BD Executive and Technical Director

By Kristin Brooks | February 3, 2014

Barish and Watt bring extensive pharmaceutical experience

Lonnie Barish has been appointed executive director of business development at WellSpring Pharma Services, and David Watt has been named technical director of Pharma Services.
Mr. Watt has more than 20 years of pharmaceutical GMP experience in technical definition and evaluation of contract development and manufacturing projects from both the provider and client side. Mr. Watt previously held positions with Valeant, Medicis, Patheon and Syntex Pharmaceuticals.
Mr. Barish has more than 20 years of experience in pharmaceutical sales, marketing and business development. Most recently he served as executive director, North America, at Nuvisan, and business development director at CoreLab Partners and AAIPharma Services Corp.
“David and Lonnie both bring extensive industry experience and have outstanding reputations within the industry,” said Sam Ricchezza, vice president, business development. “I am excited to have these two outstanding individuals on board to help us continue building upon our leadership position in the global pharmaceutical manufacturing services business.”
"We are excited with the additions of these two key appointments to the WellSpring Pharma Services team." said Wendy Shusko, president of WellSpring Pharmaceutical Corp. “Lonnie and David bring a great deal of business development experience and technical knowledge to our company and will no doubt have a tremendous impact on our company as we grow our business."

blog comments powered by Disqus
  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision

  • The Impact of Sample Handling  and Processing on the Outcome of Bioanalytical Testing

    The Impact of Sample Handling and Processing on the Outcome of Bioanalytical Testing

    Haiko Pillu, Head Technical Operations, Life Science Services, SGS Belgium NV||September 8, 2016
    Optimizing bioanalytical procedures to get reliable results in clinical studies

  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture